23:46 , Sep 19, 2017 |  BC Extra  |  Company News

Management tracks: OncoMed, Vividion, Spero

Cancer company OncoMed Pharmaceuticals Inc. (NASDAQ:OMED) said Chairman and CEO Paul Hastings began a medical leave of absence. Proteomics company Vividion Therapeutics Inc. (San Diego, Calif.) named Diego Miralles CEO. He was president of the...
03:12 , Dec 1, 2016 |  BC Week In Review  |  Financial News

Rosetta Genomics completes direct public offering and private placement

Rosetta raised $5 million in a registered direct offering of shares and convertible debentures and a concurrent private placement of unregistered convertible debentures and warrants. The company raised $547,500 through the sale of 1.1 million...
08:00 , Nov 2, 2015 |  BC Week In Review  |  Clinical News

RosettaGX Reveal: Clinical trial data

Data from 192 fine needle aspiration (FNA) smears in a blinded, international validation study showed that when the final diagnosis was unanimously confirmed by 3 pathologists, Rosetta’s RosettaGX Reveal assay had 95% sensitivity, 79% specificity,...
07:00 , Oct 26, 2015 |  BC Week In Review  |  Company News

Rosetta Genomics sales and marketing update

Rosetta launched a BRAF mutation analysis test for use in melanoma and colon cancer. Rosetta Genomics Ltd. (NASDAQ:ROSG), Rehovot, Israel   Business: Diagnostic  ...
07:00 , Oct 19, 2015 |  BC Week In Review  |  Financial News

Rosetta Genomics completes private placement of units

Rosetta Genomics Ltd. (NASDAQ:ROSG), Rehovot, Israel   Business: Diagnostic   Date completed: 2015-10-14   Type: Private placement of units   Raised: $8 million   Units: 3.3 million   Price: $2.40 (unit)   Shares after offering:...
07:00 , Jul 13, 2015 |  BC Week In Review  |  Company News

Rosetta Genomics sales and marketing update

Rosetta launched two fibroblast growth factor (FGF) receptor 3 ( FGFR3 ; CD333 ) gene mutation assays. The first detects the recurrence of FGFR3-positive low-grade bladder cancer from urine. The second, in conjunction with antigen...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Prelude, Rosetta Genomics deal

Rosetta Genomics acquired fellow molecular diagnostics and services company PersonalizeDx from Prelude for $2 million in cash and 500,000 Rosetta shares valued at $1.5 million based on Rosetta’s close of $2.95 on April 8, before...
07:00 , May 4, 2015 |  BC Week In Review  |  Company News

Rosetta Genomics, Admera Health sales and marketing update

Rosetta launched Admera’s laboratory developed test (LDT), OncoGxOne to detects alterations in 64 genes implicated in cancer and chemotherapy. Rosetta has rights to the test under a 2014 deal. Rosetta Genomics Ltd. (NASDAQ:ROSG), Rehovot, Israel...
07:00 , Mar 9, 2015 |  BC Week In Review  |  Company News

Precipio, Rosetta Genomics deal

Precipio granted Rosetta the right to co-promote diagnostic cancer tests in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia and Washington, D.C. The companies said they expect to expand the deal. Precipio markets bone marrow and...
07:00 , Sep 1, 2014 |  BC Week In Review  |  Company News

Rosetta Genomics deal

Rosetta said it will provide its microRNA profiling and other services in a deal with an undisclosed pharmaceutical company to develop a miRNA-based diagnostic for early detection of Alzheimer’s disease (AD). Rosetta declined to disclose...